UTI Flexi cap mutual fund review: Strong long-term track record

ET Wealth collaborates with Value Research to analyse top mutual funds. We examine the key fundamentals of the fund, its portfolio and performance to help you make an informed investment decision.

BASIC FACTS
DATE OF LAUNCH
18 MAY 1992
CATEGORY

EQUITY
TYPE
FLEXI CAP
AUM*
Rs.26,503 crore
BENCHMARK
NIFTY 500 TOTAL
RETURN INDEX

WHAT IT COSTS
NAV**
GROWTH OPTION
Rs.237.24
IDCW
Rs.156.85
MINIMUM INVESTMENT
Rs.5,000
MINIMUM SIP AMOUNT
Rs.500
EXPENSE RATIO*** (%)
1.82
EXIT LOAD
For units in excess of 10% of the investment,1% will be charged for redemption within 365 days

*AS ON 31 AUGUST 2022
**AS ON 27 SEPTEMBER 2022
***AS ON 31 AUGUST 2022

FUND MANAGER
AJAY TYAGI
TENURE: 6 YEARS, 7 MONTHS

Recent portfolio changes
Complete Exits: Cera Sanitaryware, La Opala RG.
Increasing allocation: 3M India, Aavas Financiers, Asian Paints, Astral, Avenue Supermarts, Berger Paints India, Coforge, ICICI Bank, Info Edge (India), MindTree, Poly Medicure, Rossari Biotech, Titan Company, Zomato.

Should you buy?
Run as a large-cap oriented fund in its earlier avatar as UTI Equity, this fund retains its large cap tilt under revised flexi cap mandate. The fund manager adopts a distinct quality and growth bias for its portfolio. It is well diversified, yet retains healthy positions in its top bets. The fund regained its consistency in outperformance soon after the current fund manager took over its reins. However, it has experienced a dip over the past year as the market preferences shifted away from growth. It continues to retain a strong long term track record and should find a way back in the hands of its proven fund manager.

(Source: Value Research)